The MOSES study is the first of its kind to compare two active treatments in the prevention of secondary stroke. It investigates whether the AIIA eprosartan (TEVETEN^®) is superior to the calcium channel blocker nitrendipine in reducing cardiovascular and cerebrovascular morbidity and mortality in patients who have suffered stroke or transient ischaemic attack (TIA). Both classes of drug have been shown to reduce the risk of primary stroke.

Eprosartan has been available since 1999 and is currently indicated for the treatment of hypertension in a broad range of patients throughout Europe and the USA. Nitrendipine was chosen as the active comparator drug in the MOSES study because of its demonstrated impact in a previous clinical study called called Syst-Eur (Systolic hypertension in Europe), in which it was shown to significantly reduce the risk of secondary stroke.